Literature DB >> 20476988

Lymphocyte homeostasis and the antitumor immune response.

Theresa L Whiteside1.   

Abstract

Lymphocyte homeostasis is regulated by proliferation of antigen-responsive T-cells in the peripheral circulation and their apoptosis. Patients with cancer have altered lymphocyte homeostasis. Spontaneous apoptosis of circulating CD8(+) antigen-responding effector T-cells contributes to rapid lymphocyte turnover and depressed absolute numbers of T-cell subsets observed in patients with cancer. A rapid transit of naive CD8(+) T-cells to the expanded memory pool and enhanced apoptosis of antitumor effector T-cells in the peripheral circulation of patients with cancer are partly responsible for this rapid lymphocyte turnover. Future strategies for restoration of normal lymphocyte homeostasis in cancer will involve therapies with survival cytokines and factors selected for extending survival of antitumor effector cells and establishing long-term immunologic memory.

Entities:  

Year:  2005        PMID: 20476988     DOI: 10.1586/1744666X.1.3.369

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  4 in total

Review 1.  Immune responses to malignancies.

Authors:  Theresa L Whiteside
Journal:  J Allergy Clin Immunol       Date:  2010-01-12       Impact factor: 10.793

2.  Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis.

Authors:  Laura Strauss; Christoph Bergmann; Theresa L Whiteside
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

3.  Prognostic role of lymphocyte to monocyte ratio in feline high-grade lymphomas.

Authors:  Michihito Tagawa; Genya Shimbo; Kazuro Miyahara
Journal:  Can Vet J       Date:  2021-10       Impact factor: 1.008

4.  Immune responses to cancer: are they potential biomarkers of prognosis?

Authors:  Theresa L Whiteside
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.